ALPHA TAU MEDICAL LTD. INTERIM CONSOLIDATED FINANCIAL STATEMENTS AS OF JUNE 30, 2024 U.S. DOLLARS IN THOUSANDS UNAUDITED INDEX Page Interim Consolidated Balance Sheets 2 - 3 Interim Consolidated Statements of Operations

ALPHA TAU MEDICAL LTD.

INTERIM CONSOLIDATED FINANCIAL STATEMENTS

U.S. DOLLARS IN THOUSANDS

ALPHA TAU MEDICAL LTD.

CONSOLIDATED BALANCE SHEETS

U.S. dollars in thousands

The accompanying notes are an integral

part of the interim consolidated financial statements.

ALPHA TAU MEDICAL LTD.

INTERIM CONSOLIDATED BALANCE SHEETS

U.S. dollars in thousands

The accompanying notes are an integral part of

the interim consolidated financial statements.

ALPHA TAU MEDICAL LTD.

INTERIM CONSOLIDATED

STATEMENTS OF OPERATIONS

U.S. dollars in thousands (except share

The accompanying notes are an integral part of

the interim consolidated financial statements.

ALPHA TAU MEDICAL LTD.

INTERIM CONSOLIDATED

STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY

U.S. dollars in thousands (except share

The accompanying notes are an integral part of

the interim consolidated unaudited financial statements.

ALPHA TAU MEDICAL LTD.

INTERIM CONSOLIDATED

STATEMENTS OF CASH FLOWS

U.S. dollars in thousands

The accompanying notes are an integral part of

the interim consolidated financial statements.

Ltd. ("the Company") is an Israeli clinical-stage oncology therapeutics company that focuses on research, development and commercialization

of Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) for the treatment of solid cancer. The Company was established in November

2015 and began its operations in January 2016, and shortly thereafter acquired the full rights to the Alpha DaRT technology from Althera

Medical Ltd., ("Althera"), developed in 2003 at Tel Aviv University.

Company established a fully owned subsidiary in the United States - "Alpha Tau Medical Inc." ("ATM Inc"). ATM Inc

began its activity in August 2018.

the Company established a subsidiary in Japan "Alpha Tau Medical KK" (hereafter: ATM KK). ATM KK began its activity in January

2018. Since July 2019, the Company holds 100% of ATM KK.

Company established a fully owned subsidiary in Canada "Alpha Tau Medical Canada Inc." (hereafter: ATM Canada Inc). ATM Canada

Inc began its activity in March 2020.

2021, the Company entered into an Agreement and Plan of Merger (the "Merger Agreement") with Healthcare Capital Corp ("HCCC"),

a Delaware corporation and special purpose acquisition company ("SPAC"), and Archery Merger Sub Inc., a wholly-owned subsidiary

of the Company ("Merger Sub"), pursuant to which Merger Sub merged with and into HCCC (the "Merger"). The Merger

was consummated on March 7, 2022, with HCCC becoming a wholly-owned subsidiary of the Company and the Company became a Nasdaq listed

publicly traded company on March 8, 2022.

to continue to incur substantial losses over the next several years during its clinical development phase. To fully execute its business

plan, the Company will need to complete registrational clinical studies and certain development activities as well as manufacture the

required clinical and commercial products in its manufacturing plants. Further, the Company will seek further regulatory approvals prior

to commercialization and the Company will need to establish sales, marketing and logistic infrastructures. These activities may span many

years and require substantial expenditures to complete and may ultimately be unsuccessful. Any delays in completing these activities could

adversely impact the Company.

As of June 30, 2024,

the Company had cash, cash equivalents, short-term deposits and restricted deposits of $74,146. During the six months period ended June

30, 2024, the Company incurred a net loss of $15,350 and had negative cash flows from operating activities of $12,803. In addition, the

Company had an accumulated deficit of $131,109 on June 30, 2024. The Company believes that its existing capital resources will be adequate

to satisfy its expected liquidity requirements for at least two years.

NOTE 2:- SIGNIFICANT

The accompanying unaudited interim

consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles ("U.S. GAAP")

for interim financial information. In the opinion of management, the unaudited interim consolidated financial statements include all adjustments

necessary for a fair presentation.

The balance sheet as of December 31,

2023 has been derived from the audited consolidated financial statements of the Company at that date but does not include all information

and footnotes required by U.S. GAAP for complete financial statements.

The accompanying unaudited interim

consolidated financial statements should be read in conjunction with the audited consolidated financial statements and accompanying notes

for the year ended December 31, 2023.

The significant accounting policies

disclosed in the Company's audited 2023 consolidated financial statements and notes thereto have been applied consistently to these unaudited

interim consolidated financial statements. Results for the six-month period ended June 30, 2024 are not necessarily indicative of results

that may be expected for the year ending December 31, 2024.

The preparation of the unaudited interim

consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect

the amounts reported in the consolidated financial statements and accompanying notes. On an ongoing basis, the Company's management

evaluates estimates, including those related to fair values of warrants, fair values of share-based awards, deferred taxes, and contingent

liabilities. Such estimates are based on historical experience and on various other assumptions that are believed to be reasonable, the

results of which form the basis for making judgments about the carrying values of assets and liabilities.

NOTE 2:- SIGNIFICANT

ACCOUNTING POLICIES (Cont.)

Restricted cash is primarily invested

in bank deposit and is used as security for the Company's lease commitments. The following table provides a reconciliation of the cash

and cash equivalents balances reported on the balance sheets and the cash, cash equivalents and restricted cash balances reported in the

statements of cash flows:

The Company determines

if an arrangement meets the definition of a lease at the inception of the lease.

Right-of-use ("ROU")

assets represent the right to use an underlying asset for the lease term and lease liabilities represent the Company's obligation

to make lease payments arising from the lease agreement. ROU assets are initially measured at amounts, which represents the discounted